n(g),n(g')-dimethyl-l-arginine and Innate Inflammatory Response studies

N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine

Research Excerpts

Excerpt	Relevance	Reference
"We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM)."	9.12	Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007)
"The aim of our study was to determine whether Dimethylarginine Dimethylaminohydrolase (DDAH) 1 and 2 gene polymorphisms - the main enzyme involved in ADMA degradation - are associated with high Asymmetric Dimethylarginine (ADMA) levels in Rheumatoid Arthritis (RA)."	7.80	Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. ( Dimitroulas, T; Hodson, J; Kitas, GD; Panoulas, VF; Sandoo, A; Smith, J, 2014)
"Endothelial dysfunction as assessed by asymmetric dimethylarginine (ADMA) and inflammation has been consistently linked to atherosclerosis, death, and cardiovascular (CV) events in ESRD patients."	7.77	Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. ( Boger, R; Maas, R; Malatino, L; Mallamaci, F; Mattace Raso, F; Rapisarda, F; Seck, MS; Sijbrands, E; Tripepi, G; Witteman, J; Zoccali, C, 2011)
"To investigate the relationship between periodontal disease indexes (PDI) and endothelial dysfunction by means of asymmetric dimethyl-arginine (ADMA) in conditions of both increased and decreased systemic inflammation in the setting of hypertension."	7.76	The conjoint detrimental effect of chronic periodontal disease and systemic inflammation on asymmetric dimethyl-arginine in untreated hypertensive subjects. ( Kasiakogias, A; Mostratou, E; Silvestros, S; Soldatos, N; Stefanadi, E; Stefanadis, C; Syrseloudis, D; Thomopoulos, C; Tsioufis, C, 2010)
"Asymmetric dimethylarginine (ADMA) assumes a significant role in atherosclerosis by inhibiting the endothelial nitric oxide synthase (eNOS)."	7.74	Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. ( Bereczki, D; Csiba, L; Gesztelyi, R; Kéki, S; Magyar, MT; Torok, J; Valikovics, A; Zsuga, J; Zsuga, M, 2007)
"The endogenous inhibitor of nitric oxide synthase (NOs) asymmetrical dimethyl-arginine (ADMA) has been implicated as a possible modulator of inducible NOs during acute inflammation."	7.74	Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. ( Boger, R; Cambareri, F; Cutrupi, S; Enia, G; Finocchiaro, P; Maas, R; Martorano, C; Panuccio, V; Pizzini, P; Schulze, F; Tripepi, G; Zoccali, C, 2007)
"Hydrogen sulfide (H2S) has attracted interest as a gaseous mediator involved in diverse processes in the nervous system, particularly with respect to learning and memory."	5.43	The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine. ( El Azhary, NM; Mostafa, DK; Nasra, RA, 2016)
"We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM)."	5.12	Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007)
" Thus, together with classic risk factors such as hypertension, dyslipidemia and diabetes, other situations such as microinflammation, increased concentration of asymmetrical dimethyl-L-arginine, disturbed phosphate metabolism and anemia may represent important risk factors for accelerated atherosclerosis in dialyzed patients."	4.82	Atherosclerosis in dialyzed patients. ( Ritz, E, 2004)
"We review the role inflammation [C-reactive protein (CRP)], hyperhomocysteinemia, high plasma norepinephrine, and accumulation of the endogenous inhibitor of the nitric oxide synthase asymmetric dimethylarginine (ADMA) in the high all-cause and CV mortality of patients on continuous ambulatory peritoneal dialysis (CAPD)."	4.82	Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. ( Enia, G; Mallamaci, F; Panuccio, V; Tripepi, G; Zoccali, C, 2005)
" The demographic parameters, Asymmetric dimethylarginine (ADMA), homeostatic model assessment of insulin resistance (HOMA-IR) index and highsensitivity C-reactive protein (hs-CRP) levels were measured."	3.88	Increased Endothelial Dysfunction and Insulin Resistance in Patients with Klinefelter Syndrome. ( Aydogdu, A; Azal, O; Basaran, Y; Demir, O; Demirci, I; Dinc, M; Haymana, C; Meric, C; Sonmez, A; Torun, D; Yesildal, F, 2018)
" Markers of endothelial dysfunction (asymmetric dimethylarginine, ADMA) and inflammation (lipoprotein-associated phospholipase A2, Lp-PLA2) were measured."	3.85	Distinct Roles of Endothelial Dysfunction and Inflammation in Intracranial Atherosclerotic Stroke. ( Bang, OY; Cho, YH; Chung, CS; Chung, JW; Kim, GM; Lee, KH; Moon, GJ; Oh, MJ, 2017)
" The aim of this study was to investigate the relationship between brachial intima-media thickness (B-IMT), an independent predictor of cardiovascular risk, systemic inflammation, and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, in patients with COPD and respective controls."	3.85	Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD. ( Burghuber, OC; Eickhoff, P; Funk, GC; Urban, MH; Valipour, A; Wolzt, M, 2017)
" Plasma MED concentrations, inflammation and oxidative stress indices [Kynurenine/Tryptophan (Kyn/Trp) ratio, malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio] were measured in 30 CKD patients randomized to three cholesterol lowering regimens for 12 months (simvastatin 40mg/day, ezetimibe/simvastatin 10/20mg/day, or ezetimibe/simvastatin 10/40mg/day)."	3.83	Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. ( Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A, 2016)
"Hypercholesterolemia is characterized by changes in lipid profile, nitric oxide pathway, and oxidative stress markers, but functions of high-density lipoprotein (HDL) were not well established in hypercholesterolemic subjects treated with atorvastatin."	3.81	The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics. ( Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A, 2015)
"We aimed to evaluate oxidative stress [8-hydroxydeoxyguanosine (8-OHdG), malondialdehyde (MDA)] endothelial damage [asymmetric dimethylarginine (ADMA)] and markers of cellular inflammation [interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), neopterin (NP) and high-sensitivity C-reactive protein (hsCRP)] in patients with diabetic nephropathy (DN) and non-diabetic nephropathy who were being administered hemodialysis treatment because of chronic renal failure."	3.80	Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. ( Agilli, M; Avci, E; Bilgi, C; Cakir, E; Cevher, SC; Yaman, H, 2014)
"The aim of our study was to determine whether Dimethylarginine Dimethylaminohydrolase (DDAH) 1 and 2 gene polymorphisms - the main enzyme involved in ADMA degradation - are associated with high Asymmetric Dimethylarginine (ADMA) levels in Rheumatoid Arthritis (RA)."	3.80	Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. ( Dimitroulas, T; Hodson, J; Kitas, GD; Panoulas, VF; Sandoo, A; Smith, J, 2014)
"To discuss the effect of matrine on nitric oxide (NO) and asymmetric methylarginine (ADMA) metabolism pathways in serum and tissues of mice with lipopolysaccharide (LPS) -induced intestine tissue inflammation."	3.80	[Effect of matrine on NO and ADMA metabolism pathways in serum and tissues of mice with lipopolysaccharide-induced intestine tissue inflammation]. ( Chen, LP; Wang, JY; Wang, Y; Wu, Y; Zhang, Y, 2014)
"Systemic inflammation and elevated circulating levels of the endogenous nitric oxide inhibitor asymmetrical dimethylarginine (ADMA) have been associated with increased risk in cardiogenic shock (CS)."	3.77	Inflammation and reduced endothelial function in the course of severe acute heart failure. ( Hermansen, SE; How, OJ; Kalstad, T; Myrmel, T, 2011)
" We found that mild hypertension, increased plasma levels of creatinine, inorganic phosphate, asymmetric dimethylarginine (ADMA), and parathyroid hormone (PTH) were observed in the present SNx rats without LVH."	3.77	Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats. ( Aizawa, K; Ishizuka, N; Iwabuchi, S; Kitamura, H; Moriguchi, Y; Nishimura, T; Serizawa, K; Tashiro, Y; Yogo, K; Yorozu, K, 2011)
"Endothelial dysfunction as assessed by asymmetric dimethylarginine (ADMA) and inflammation has been consistently linked to atherosclerosis, death, and cardiovascular (CV) events in ESRD patients."	3.77	Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. ( Boger, R; Maas, R; Malatino, L; Mallamaci, F; Mattace Raso, F; Rapisarda, F; Seck, MS; Sijbrands, E; Tripepi, G; Witteman, J; Zoccali, C, 2011)
"Asymmetric dimethylarginine (ADMA) and subclinical inflammation are associated with atherosclerosis progression, whereas microalbuminuria is an established index of hypertensive organ damage."	3.76	ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. ( Andrikou, E; Dimitriadis, K; Mihas, C; Miliou, A; Papademetriou, V; Stefanadi, E; Stefanadis, C; Thomopoulos, C; Tsiachris, D; Tsioufis, C, 2010)
"Adipokines such as leptin and adiponectin are adipocyte-specific secretory proteins that play important roles in the metabolic regulation of body weight, insulin resistance and cardiovascular complications."	3.76	Adipokines, endothelial dysfunction and nutritional status in peritoneal dialysis patients. ( Aleksandrowicz-Wrona, E; Lichodziejewska-Niemierko, M; Małgorzewicz, S; Rutkowski, B; Świetlik, D; Łysiak-Szydłowska, W, 2010)
"To investigate the relationship between periodontal disease indexes (PDI) and endothelial dysfunction by means of asymmetric dimethyl-arginine (ADMA) in conditions of both increased and decreased systemic inflammation in the setting of hypertension."	3.76	The conjoint detrimental effect of chronic periodontal disease and systemic inflammation on asymmetric dimethyl-arginine in untreated hypertensive subjects. ( Kasiakogias, A; Mostratou, E; Silvestros, S; Soldatos, N; Stefanadi, E; Stefanadis, C; Syrseloudis, D; Thomopoulos, C; Tsioufis, C, 2010)
"The endogenous inhibitor of nitric oxide synthase (NOs) asymmetrical dimethyl-arginine (ADMA) has been implicated as a possible modulator of inducible NOs during acute inflammation."	3.74	Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. ( Boger, R; Cambareri, F; Cutrupi, S; Enia, G; Finocchiaro, P; Maas, R; Martorano, C; Panuccio, V; Pizzini, P; Schulze, F; Tripepi, G; Zoccali, C, 2007)
"Asymmetric dimethylarginine (ADMA) assumes a significant role in atherosclerosis by inhibiting the endothelial nitric oxide synthase (eNOS)."	3.74	Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. ( Bereczki, D; Csiba, L; Gesztelyi, R; Kéki, S; Magyar, MT; Torok, J; Valikovics, A; Zsuga, J; Zsuga, M, 2007)
" Covariates that were considered for adjustment included clinical characteristics, baseline GFR (Modification of Diet in Renal Disease equation 7 formula), proteinuria, traditional cardiovascular risk factors, serum C-reactive protein, homocysteine, and concomitant therapies."	3.73	Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. ( Malberti, F; Mallamaci, F; Ravani, P; Testa, S; Tripepi, G; Zoccali, C, 2005)
" Abnormalities in coronary microvascular function result from increased microvascular resistances and impaired endothelial release of vasoactive substances, especially in production and bioavailability of endothelium derived NO."	2.47	Peripheral hemorheological and vascular correlates of coronary blood flow. ( Damaske, A; Fasola, F; Fineschi, M; Forconi, S; Gori, T; Jabs, A; Munzel, T; Muxel, S; Orphal, D; Parker, JD; Radmacher, MC; Schaefer, S; Wild, P, 2011)
"HIV infection and type 2 diabetes are associated with altered gut microbiota, chronic inflammation, and increased cardiovascular risk."	1.48	Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction. ( Aukrust, P; Gaardbo, JC; Gelpi, M; Gerstoft, J; Hoel, H; Holm, K; Hov, JR; Hove-Skovsgaard, M; Kummen, M; Nielsen, SD; Nwosu, F; Rudi, K; Seljeflot, I; Trøseid, M; Ueland, PM; Ullum, H; Valeur, J, 2018)
"In elderly COPD people, increased arterial stiffness is related to reduced pulmonary function and it seems worth testing as a potential marker of higher cardiovascular risk."	1.46	Relationship between FEV ( Antonelli-Incalzi, R; Battistoni, F; Chiurco, D; Costanzo, L; Pedone, C; Santangelo, S, 2017)
"Subclinical hypothyroidism is associated with increased levels of serum endocan, ADMA, and TGF-β, which are new markers for ED."	1.43	Endocan, TGF-beta, and ADMA as Risk Factors for Endothelial Dysfunction and Possible Vascular Disease in Patients with Subclinical Hypothyroidism. ( Arpaci, D; Ciftci, IH; Ergenc, H; Gurol, G; Karakece, E; Tamer, A; Tocoglu, AG, 2016)
"Hydrogen sulfide (H2S) has attracted interest as a gaseous mediator involved in diverse processes in the nervous system, particularly with respect to learning and memory."	1.43	The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine. ( El Azhary, NM; Mostafa, DK; Nasra, RA, 2016)
"Carotid atherosclerosis was evaluated by ultrasonographically determined intima-media thickness (IMT)."	1.42	Asymmetric dimethylarginine is associated with high-sensitivity C-reactive protein and early carotid atherosclerosis in women with previous gestational diabetes mellitus. ( Li, D; Shao, Y; Xia, W; Xu, L; Xu, W; Zhang, C, 2015)
"A low peak reactive hyperemia and a low PAT hyperemia ratio before the bicycle test was associated with a high percentage increase in peak reactive hyperemia after exercise (r = - 0."	1.42	Exercise-induced vasodilation in healthy males: A marker of reduced endothelial function. ( Kjekshus, J; Røysland, R; Torbjørn, O; Wethal, T, 2015)
"Like rheumatoid arthritis, ankylosing spondylitis (AS) is also an inflammatory disease associated with accelerated atherosclerosis and the presence of metabolic syndrome (MeS) features."	1.40	IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy. ( Blanco, R; Carnero-López, B; Genre, F; Gómez-Acebo, I; González-Gay, MA; González-Juanatey, C; Llorca, J; López-Mejías, R; Miranda-Filloy, JA; Pina, T; Rueda-Gotor, J; Ubilla, B; Villar-Bonet, A, 2014)
" As assessed by the ratio of L-arginine/asymmetric dimethylarginine, the bioavailability of nitric oxide was shown to be reduced in hepatic IRI, especially in those patients suffering from perfusion disorders following liver transplantation."	1.39	Reactive metabolites and AGE-RAGE-mediated inflammation in patients following liver transplantation. ( Brenner, T; Bruckner, T; Fleming, TH; Hofer, S; Martin, EO; Schemmer, P; Spranz, D; Uhle, F; Weigand, MA, 2013)
"Inflammation was assessed by high-sensitivity C-reactive protein (hs-CRP) levels."	1.36	The effects of endothelial dysfunction and inflammation on slow coronary flow. ( Arı, H; Arı, S; Bozat, T; Erdoğan, E; Huysal, K; Koca, V; Tiryakioğlu, O, 2010)
" Hemodynamic and metabolic variables and dosage of vasopressor medications were recorded for the first 12 hours of intensive care unit admission after cardiac surgery on an electronic patient record."	1.33	Gene polymorphism and requirement for vasopressor infusion after cardiac surgery. ( Duggan, E; Kelleher, D; McGovern, E; McManus, R; O'Dwyer, MJ; Ryan, AW; Ryan, R; Ryan, T; Thornton, J, 2006)

Research

Studies (86)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Mean Change in Endothelial Function Biomarker Asymmetrical DiMethylArginine (ADMA) Over 12 Weeks

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (20.93)	29.6817
2010's	62 (72.09)	24.3611
2020's	6 (6.98)	2.80

Authors	Studies
Abdel-Magied, N	1
Shedid, SM	1
Yang, D	1
Yang, Z	1
Chen, L	1
Kuang, D	1
Zou, Y	1
Li, J	2
Deng, X	1
Luo, S	1
Luo, J	1
He, J	3
Yan, M	1
He, G	1
Deng, Y	1
Li, R	1
Yuan, Q	1
Zhou, Y	1
Jiang, P	1
Tan, S	1
Yilmaz, MI	1
Romano, M	1
Basarali, MK	1
Elzagallaai, A	1
Karaman, M	1
Demir, Z	1
Demir, MF	1
Akcay, F	1
Seyrek, M	1
Haksever, N	1
Piskin, D	1
Cimaz, R	1
Rieder, MJ	1
Demirkaya, E	1
Corrêa, HL	1
Moura, SRG	1
Neves, RVP	1
Tzanno-Martins, C	1
Souza, MK	1
Haro, AS	1
Costa, F	1
Silva, JAB	1
Stone, W	1
Honorato, FS	1
Deus, LA	1
Prestes, J	1
Simões, HG	1
Vieira, EC	1
de Melo, GF	1
Moraes, MR	1
Rosa, TS	1
Chen, J	2
Hamm, LL	2
Bundy, JD	1
Kumbala, DR	1
Bodana, S	1
Chandra, S	1
Chen, CS	2
Starcke, CC	1
Guo, Y	1
Schaefer, CM	1
Lustigova, E	1
Mahone, E	1
Vadalia, AM	1
Livingston, T	1
Obst, K	1
Hernandez, J	1
Bokhari, SR	1
Kleinpeter, M	1
Alper, AB	1
Lukitsch, I	1
He, H	1
Nieman, DC	1
Mangoni, AA	2
Tommasi, S	1
Sotgia, S	2
Zinellu, A	2
Paliogiannis, P	1
Piga, M	1
Cauli, A	1
Pintus, G	1
Carru, C	2
Erre, GL	1
Hove-Skovsgaard, M	2
Gaardbo, JC	2
Kolte, L	1
Winding, K	1
Seljeflot, I	2
Svardal, A	1
Berge, RK	1
Gerstoft, J	2
Ullum, H	2
Trøseid, M	2
Nielsen, SD	2
Dogan, I	1
Dogan, T	1
Yetim, M	1
Kayadibi, H	1
Yilmaz, MB	1
Eser, B	1
Kalcik, M	1
Karavelioglu, Y	1
Chung, JW	1
Oh, MJ	1
Cho, YH	1
Moon, GJ	1
Kim, GM	1
Chung, CS	1
Lee, KH	1
Bang, OY	1
Haymana, C	1
Aydogdu, A	1
Demirci, I	1
Dinc, M	1
Demir, O	1
Torun, D	1
Yesildal, F	1
Meric, C	1
Basaran, Y	1
Sonmez, A	1
Azal, O	1
Hoel, H	1
Hov, JR	1
Holm, K	1
Kummen, M	1
Rudi, K	1
Nwosu, F	1
Valeur, J	1
Gelpi, M	1
Ueland, PM	1
Aukrust, P	2
Wielkoszyński, T	1
Zalejska-Fiolka, J	1
Strzelczyk, JK	1
Owczarek, AJ	1
Cholewka, A	1
Furmański, M	1
Stanek, A	1
Ağbaş, A	1
Canpolat, N	1
Çalışkan, S	1
Yılmaz, A	1
Ekmekçi, H	1
Mayes, M	1
Aitkenhead, H	1
Schaefer, F	1
Sever, L	1
Shroff, R	1
Pajek, M	1
Jerman, A	1
Osredkar, J	1
Ponikvar, JB	1
Pajek, J	1
Tahara, N	1
Kojima, R	1
Yoshida, R	1
Bekki, M	1
Sugiyama, Y	1
Tahara, A	1
Maeda, S	1
Honda, A	1
Igata, S	1
Nakamura, T	1
Sun, J	1
Matsui, T	2
Fukumoto, Y	1
Yamagishi, SI	1
Dimitroulas, T	3
Kitas, GD	3
Ding, L	1
Cheng, P	1
Wang, L	2
Hu, J	1
Zhang, YX	1
Cai, GW	1
Huang, GY	1
Gao, S	1
Ignjatović, AM	1
Cvetković, TP	1
Pavlović, RM	1
Đorđević, VM	1
Milošević, ZG	1
Đorđević, VB	1
Pavlović, DD	1
Stojanović, IR	1
Bogdanović, D	1
Lau, EM	1
Morgan, PE	1
Belousova, EG	1
Toelle, BG	1
Ayer, JG	1
Celermajer, DS	1
Marks, GB	1
Brenner, T	1
Fleming, TH	1
Spranz, D	1
Schemmer, P	1
Bruckner, T	1
Uhle, F	1
Martin, EO	1
Weigand, MA	1
Hofer, S	1
Spinelli, FR	1
Metere, A	1
Barbati, C	1
Pierdominici, M	1
Iannuccelli, C	1
Lucchino, B	1
Ciciarello, F	1
Agati, L	1
Valesini, G	1
Di Franco, M	1
Lindgren, C	1
Hultin, M	2
Koskinen, LO	2
Lindvall, P	1
Borota, L	1
Naredi, S	2
Halici, B	2
Sarinc Ulasli, S	1
Günay, E	2
Nural, S	2
Sen, S	1
Akar, O	1
Celik, S	3
Unlu, M	2
Avci, E	1
Cakir, E	1
Cevher, SC	1
Yaman, H	1
Agilli, M	1
Bilgi, C	1
Ali, OA	1
Chapman, M	1
Nguyen, TH	1
Chirkov, YY	1
Heresztyn, T	1
Mundisugih, J	1
Horowitz, JD	1
Xia, W	2
Li, D	1
Zhang, C	1
Xu, L	1
Xu, W	1
Shao, Y	1
Sandoo, A	2
Hodson, J	2
Smith, JP	1
Douglas, KM	1
Smith, J	1
Panoulas, VF	1
Wu, Y	1
Wang, Y	1
Zhang, Y	2
Chen, LP	1
Wang, JY	1
Genre, F	1
López-Mejías, R	1
Rueda-Gotor, J	1
Miranda-Filloy, JA	1
Ubilla, B	1
Villar-Bonet, A	1
Carnero-López, B	1
Gómez-Acebo, I	1
Blanco, R	1
Pina, T	1
González-Juanatey, C	1
Llorca, J	1
González-Gay, MA	1
Garcia-Martinez, R	1
Andreola, F	1
Mehta, G	1
Poulton, K	1
Oria, M	1
Jover, M	1
Soeda, J	1
Macnaughtan, J	1
De Chiara, F	1
Habtesion, A	1
Mookerjee, RP	1
Davies, N	1
Jalan, R	1
Yuksel, M	1
Yildiz, A	1
Oylumlu, M	1
Turkcu, FM	1
Bilik, MZ	1
Ekinci, A	1
Elbey, B	1
Tekbas, E	1
Alan, S	1
Wethal, T	1
Røysland, R	1
Torbjørn, O	1
Kjekshus, J	2
Akalin Çiftçi, G	1
Ertorun, İ	1
Akalin, A	1
Alataş, İÖ	1
Musmul, A	1
Mohler, ER	1
Hudaihed, A	1
Arora, R	1
Liu, Y	1
Browne, G	1
Mills, KT	1
Kleinpeter, MA	1
Simon, EE	1
Rifai, N	1
Klag, MJ	1
Boga, S	1
Alkim, H	1
Koksal, AR	1
Bayram, M	1
Ozguven, MB	1
Ergun, M	1
Neijmann, ST	1
Ozgon, G	1
Alkim, C	1
Dounousi, E	1
Torino, C	1
Pizzini, P	2
Cutrupi, S	2
Panuccio, V	3
D'Arrigo, G	1
Abd ElHafeez, S	1
Tripepi, G	6
Mallamaci, F	5
Zoccali, C	7
Costanzo, L	1
Pedone, C	1
Battistoni, F	1
Chiurco, D	1
Santangelo, S	1
Antonelli-Incalzi, R	1
Mostafa, DK	1
El Azhary, NM	1
Nasra, RA	1
Simó-Servat, O	1
Simó, R	1
Hernández, C	1
Sotgiu, E	1
Ena, S	1
Satta, AE	1
Czarnecka, A	1
Milewski, K	1
Zielińska, M	1
Arpaci, D	1
Karakece, E	1
Tocoglu, AG	1
Ergenc, H	1
Gurol, G	1
Ciftci, IH	1
Tamer, A	1
Ozalper, V	1
Kara, M	1
Tanoglu, A	1
Cetındaglı, I	1
Ozturker, C	1
Hancerlı, Y	1
Hıra, S	1
Kara, K	1
Beyazıt, Y	1
Yazgan, Y	1
Urban, MH	1
Eickhoff, P	1
Funk, GC	1
Burghuber, OC	1
Wolzt, M	1
Valipour, A	1
Thomopoulos, C	3
Tsioufis, C	3
Dimitriadis, K	2
Tsiachris, D	2
Tousoulis, D	1
Manolis, A	1
Alchanatis, M	1
Kallikazaros, I	1
Stefanadis, C	3
Terekeci, HM	1
Oktenli, C	1
Ozgurtas, T	1
Nalbant, S	1
Top, C	1
Tapan, S	1
Kucukardali, Y	1
Sanisoglu, YS	1
Solmazgul, E	1
Sahan, B	1
Sayan, O	1
Surdacki, A	1
Zhou, QG	1
Zhou, M	1
Hou, FF	1
Peng, X	1
Soldatos, N	1
Syrseloudis, D	1
Kasiakogias, A	1
Silvestros, S	1
Stefanadi, E	2
Mostratou, E	1
Ahmad, T	2
Mabalirajan, U	2
Ghosh, B	2
Agrawal, A	2
Karu, I	1
Taal, G	1
Zilmer, K	1
Pruunsild, C	1
Starkopf, J	1
Zilmer, M	1
Feng, W	1
Guan, M	1
Yu, Y	1
Qu, X	1
Andrikou, E	1
Mihas, C	1
Miliou, A	1
Papademetriou, V	1
Nakhjavani, M	1
Karimi-Jafari, H	1
Esteghamati, A	1
Khalilzadeh, O	1
Asgarani, F	1
Ghadiri-Anari, A	1
Małgorzewicz, S	1
Lichodziejewska-Niemierko, M	1
Aleksandrowicz-Wrona, E	1
Świetlik, D	1
Rutkowski, B	1
Łysiak-Szydłowska, W	1
Blackwell, S	1
O'Reilly, DS	1
Reid, D	1
Talwar, D	1
Arı, H	1
Arı, S	1
Erdoğan, E	1
Tiryakioğlu, O	1
Huysal, K	1
Koca, V	1
Bozat, T	1
Hermansen, SE	1
Kalstad, T	1
How, OJ	1
Myrmel, T	1
Moriguchi, Y	1
Yogo, K	1
Aizawa, K	1
Serizawa, K	1
Tashiro, Y	1
Yorozu, K	1
Ishizuka, N	1
Iwabuchi, S	1
Kitamura, H	1
Nishimura, T	1
Mattace Raso, F	1
Sijbrands, E	1
Seck, MS	1
Maas, R	2
Boger, R	2
Witteman, J	1
Rapisarda, F	1
Malatino, L	1
Damaske, A	1
Muxel, S	1
Fasola, F	1
Radmacher, MC	1
Schaefer, S	1
Jabs, A	1
Orphal, D	1
Wild, P	1
Parker, JD	1
Fineschi, M	1
Munzel, T	1
Forconi, S	1
Gori, T	1
Atzeni, F	1
Turiel, M	1
Boccassini, L	1
Sitia, S	1
Tomasoni, L	1
Battellino, M	1
Marchesoni, A	1
De Gennaro Colonna, V	1
Sarzi-Puttini, P	1
Baker, JV	1
Neuhaus, J	1
Duprez, D	1
Freiberg, M	1
Bernardino, JI	1
Badley, AD	1
Nixon, DE	1
Lundgren, JD	1
Tracy, RP	1
Neaton, JD	1
Hojs, R	1
Bevc, S	1
Ekart, R	1
Rodling-Wahlström, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial[NCT02552888]	Phase 2	70 participants (Actual)	Interventional	2016-03-31	Completed
The Effects of Haemodiafiltration (HDF) vs Conventional Haemodialysis (HD) on Growth and Cardiovascular Markers in Children - 3H (HDF, Hearts and Height) Study[NCT02063776]		150 participants (Actual)	Observational	2014-02-28	Active, not recruiting
Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258]		102 participants (Actual)	Observational	2015-09-30	Completed
Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234]	Phase 4	32 participants (Actual)	Interventional	2010-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A blood sample was drawn for each participant to measure the levels of Asymmetrical DiMethylArginine (ADMA). The mean changes between baseline, 6 weeks and 12 weeks in ADMA with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Endothelial Function Biomarker Endostatin Over 12 Weeks

Intervention	umol/mL (Mean)
Treatment	0.03
Placebo	0.02

A blood sample was drawn for each participant to measure the levels of endostatin. The mean changes between baseline, 6 weeks and 12 weeks in endostatin with 95% CI were calculated using linear mixed effects model, and the log transformed endostatin was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Endothelial Function Biomarker Urine Epidermal Growth Factor (UEGF) Over 12 Weeks

Intervention	log (ng/mL) (Mean)
Treatment	-0.02
Placebo	-0.01

A urine sample was taken for each participant to measure the levels of Urine Epidermal Growth Factor (UEGF). The mean changes between baseline, 6 weeks and 12 weeks in UEGF with 95% CI were calculated using linear mixed effects model, and the log transformed Urine EGF/creatinine ratio was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Estimated-Glomerular Filtration Rate (eGFR) Over 12 Weeks

Intervention	log (pg/g) (Mean)
Treatment	-0.01
Placebo	0.23

Estimated-Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The equation is GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black]. Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. The mean changes between baseline, 6 weeks and 12 weeks in eGFR with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Hemoglobin Over 12 Weeks

Intervention	mL/min/1.73 m^2 (Mean)
Treatment	0.1
Placebo	0.2

A blood sample was drawn for each participant to measure the levels of hemoglobin. The mean changes between baseline, 6 weeks and 12 weeks in hemoglobin with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: baseline, 6 weeks, 12 weeks

Mean Change in Inflammatory Biomarker C-Reactive Protein (CRP) Over 12 Weeks

Intervention	g/dL (Mean)
Treatment	-0.25
Placebo	-0.13

A blood sample was drawn for each participant to measure the levels of C-Reactive Protein (CRP). The mean changes between baseline, 6 weeks and 12 weeks in CRP with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Inflammatory Biomarker Interleukin-6 (IL-6) Over 12 Weeks

Intervention	mg/mL (Mean)
Treatment	0.05
Placebo	-0.02

A blood sample was drawn for each participant to measure the levels of interleukin-6 (IL-6). The mean changes between baseline, 6 weeks and 12 weeks in interleukin-6 (IL-6) with 95% CI were calculated using linear mixed effects model, and the log transformed IL-6 was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Isoquercetin Over 12 Weeks

Intervention	log (pg/mL) (Mean)
Treatment	0.07
Placebo	-0.17

A blood sample was drawn for each participant to measure the levels of isoquercetin. The mean changes between baseline, 6 weeks and 12 weeks in isoquercetin with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Lipid Profile Biomarker Triglycerides Over 12 Weeks

Intervention	ug/L (Mean)
Treatment	166
Placebo	11.7

A blood sample was drawn for each participant to measure the levels of triglycerides. The mean changes between baseline and 12 weeks in triglycerides with 95% CI were calculated using linear mixed effects model, and the log transformed triglyceride was calculated. (NCT02552888)
Timeframe: Baseline,12 weeks

Mean Change in Oxidative Stress Biomarker Low-density Lipoprotein (LDL) Over 12 Weeks

Intervention	log (mg/dL) (Mean)
Treatment	-0.09
Placebo	-0.01

A blood sample was drawn for each participant to measure the levels of low-density lipoprotein (LDL). The mean changes between baseline, 6 weeks and 12 weeks in LDL with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Oxidative Stress Biomarker Nitrotyrosine Over 12 Weeks

Intervention	ng/mL (Mean)
Treatment	-1.7
Placebo	-0.3

A blood sample was drawn for each participant to measure the levels of nitrotyrosine. The mean changes between baseline, 6 weeks and 12 weeks in nitrotyrosine with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Plasma Nitrate Over 12 Weeks

Intervention	pg/mL (Mean)
Treatment	-10.9
Placebo	62.2

A blood sample was drawn for each participant to measure the levels of plasma nitrate. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrate with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Plasma Nitrite Over 12 Weeks

Intervention	umol/L (Mean)
Treatment	15.4
Placebo	-6.3

A blood sample was drawn for each participant to measure the levels of plasma nitrite. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrite with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Pulse Over 12 Weeks

Intervention	micromol/L (Mean)
Treatment	-0.07
Placebo	-0.11

Pulse was measured at the brachial artery per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in pulse with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Urinary Albumin-to-creatinine Ratios Over 12 Weeks

Intervention	beat/minute (Mean)
Treatment	0.6
Placebo	-0.5

A urine sample was taken for each participant to measure the levels of urinary albumin-to-creatinine ratios. The mean changes between baseline, 6 weeks and 12 weeks in urinary albumin-to-creatinine ratios with 95% CI were calculated using linear mixed effects model, and the log transformed urinary albumin-to-creatinine ratios was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks

Intervention	log (mg/g) (Mean)
Treatment	0.04
Placebo	0.02

FMD was measured using high resolution ultrasound on the brachial artery. FMD was calculated as the maximal percentage change in vessel size during hyperemia . The mean changes between baseline, 6 weeks and 12 weeks in FMD with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Percentage Change in Methemoglobin Over 12 Weeks

Intervention	Percentage change (Mean)
Treatment	1.1
Placebos	0.3

A blood sample was drawn for each participant to measure the levels of methemoglobin. The mean percentage change between baseline, 6 weeks and 12 weeks in methemoglobin with 95% CI was calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Blood Pressure Over 12 Weeks

Intervention	Percentage change (Mean)
Treatment	-0.06
Placebo	-0.05

Blood pressure was measured using the OMRON HEM-907 XL BP Monitor per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in blood pressure with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Endothelial Function Biomarkers VCAM-1, ICAM-1, E-selectin and vWF Over 12 Weeks

Intervention	mm Hg (Mean)
	Systolic blood pressure, mmHg	Diastolic blood pressure, mmHg
Placebo	-0.7	0.1
Treatment	-2.2	-2.5

A blood sample was drawn for each participant to measure the levels of Vascular Adhesion Molecule-1(VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1), E-selectin, and von Willebrand Factor (vWF). The mean changes between baseline, 6 weeks and 12 weeks in VCAM-1, ICAM-1, E-selectin and vWF with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Inflammatory Biomarkers Tumor Necrosis Factor-α (TNF-a), Interleukin-17 (IL-17), Interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1) Over 12 Weeks

Intervention	ng/mL (Mean)
	ICAM, ng/mL	VCAM-1, ng/mL	E-Selecint, ng/mL	vWF, ng/mL
Placebo	-4.0	-10.8	1.06	2744
Treatment	-16.1	-22.2	-0.32	-683

A blood sample was drawn for each participant to measure the levels of Tumor Necrosis Factor-α (TNF-a), interleukin-17 (IL-17), interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1). The mean changes between baseline, 6 weeks and 12 weeks in TNF-a, IL-17, IL-1beta, MCP-1 with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks

Mean Change in Lipid Profile Biomarkers Total Cholesterol, Low Density Lipoprotein (LDL)-Cholesterol and High Density Lipoprotein (HDL)-Cholesterol Over 12 Weeks

Intervention	pg/mL (Mean)
	TNF-a, pg/mL	IL-17, pg/mL	IL-1 beta, pg/mL	MCP-1, pg/mL
Placebo	-0.04	0.01	-30.5	0.6
Treatment	-0.04	-0.72	-17.1	-6.0

A blood sample was drawn for each participant to measure the levels of total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol. The mean changes between baseline and 12 weeks in total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline,12 weeks

Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

Intervention	mg/dL (Mean)
	Total Cholesterol, mg/dL	LDL-cholesterol, mg/dL	HDL-cholesterol, mg/dL
Placebo	3.9	0.9	2.2
Treatment	-1.6	-1.9	0.9

Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12

Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups

Intervention	millimeter, mercury (Least Squares Mean)
Nebivolol	-0.66
Metoprolol	-2.35

The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

Intervention	percent change (Least Squares Mean)
Nebivolol	2.16
Metoprolol	10.43

"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12

Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.

Intervention	millimeter, Mercury (Least Squares Mean)
Nebivolol	-1.07
Metoprolol	-3.19

Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients < 50 Years Old Compared With Metoprolol in Transplant Recipients < 50 Years Old

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients <50 Years Old Compared With Metoprolol in Transplant Recipients >/= 50 Years Old.

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Metoprolol in Transplant Recipients Age >/= 50 Years Old.

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-twelve of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Nebivolol in Transplant Recipients < 50 Years Old.

Plasma Nitric Oxide Level (Nmol/L) at Month-12 Between the Groups.

Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.

Intervention	percent change (Least Squares Mean)
Nebivolol	-8.14
Metoprolol	8.70

Intervention	percent change (Least Squares Mean)
Nebivolol < 50 Years Old	51.55
Metoprolol <50 Years Old	-16.64

Intervention	percent change (Least Squares Mean)
Nebivolol <50 Year Old	51.55
Metoprolol >/= 50 Year Old	-17.99

Intervention	percent change (Least Squares Mean)
Nebivolol >/=50 Years Old	-15.25
Metoprolol >/=50 Years Old	-17.99

Intervention	percent change (Least Squares Mean)
Nebivolol >/=50 Years Old	-15.25
Metoprolol <50 Years Old	-16.64

Intervention	nmol/L (Least Squares Mean)
Nebivolol	50.07
Metoprolol	38.13

Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups

Intervention	percent change (Least Squares Mean)
Nebivolol	11.47
Metoprolol	-17.27

Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12

Reviews

15 reviews available for n(g),n(g')-dimethyl-l-arginine and Innate Inflammatory Response

Trials

8 trials available for n(g),n(g')-dimethyl-l-arginine and Innate Inflammatory Response

Other Studies

63 other studies available for n(g),n(g')-dimethyl-l-arginine and Innate Inflammatory Response

Article	Year
Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis? Current pharmaceutical design, 2021, Volume: 27, Issue:18 Topics: Arginine; Arthritis, Rheumatoid; Atherosclerosis; Endothelial Cells; Endothelium, Vascular; Humans;	2021
Genetic regulation of dimethylarginines and endothelial dysfunction in rheumatoid arthritis. Amino acids, 2019, Volume: 51, Issue:7 Topics: Arginine; Arthritis, Rheumatoid; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Endothelium,	2019
Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology. Journal of diabetes research, 2016, Volume: 2016 Topics: Adrenomedullin; Arginine; Autoantibodies; Basement Membrane; Biomarkers; C-Reactive Protein; Collage	2016
Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association? Neurochemical research, 2017, Volume: 42, Issue:3 Topics: Animals; Arginine; Brain; Cognition Disorders; Endothelium, Vascular; Hepatic Encephalopathy; Humans	2017
L-arginine analogs--inactive markers or active agents in atherogenesis? Cardiovascular & hematological agents in medicinal chemistry, 2008, Volume: 6, Issue:4 Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Disease; Endothelium, Vascular; Humans; Inflammation	2008
Emerging interface between metabolic syndrome and asthma. American journal of respiratory cell and molecular biology, 2011, Volume: 44, Issue:3 Topics: Animals; Arginase; Arginine; Asthma; Humans; Hyperinsulinism; Inflammation; Insulin; Insulin Resista	2011
Peripheral hemorheological and vascular correlates of coronary blood flow. Clinical hemorheology and microcirculation, 2011, Volume: 49, Issue:1-4 Topics: Arginine; Blood Flow Velocity; Chest Pain; Coronary Circulation; Diagnosis, Differential; Endotheliu	2011
Cardiovascular involvement in psoriatic arthritis. Reumatismo, 2011, Nov-09, Volume: 63, Issue:3 Topics: Antirheumatic Agents; Arginine; Arthritis, Psoriatic; Coronary Circulation; Coronary Disease; Cytoki	2011
Biomarkers in hemodialysis patients. Advances in clinical chemistry, 2012, Volume: 57 Topics: Animals; Arginine; Biomarkers; Cardiovascular Physiological Phenomena; Cell Adhesion Molecules; Huma	2012
The impact of asymmetric dimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage. Current pharmaceutical design, 2013, Volume: 19, Issue:1 Topics: Animals; Apoptosis; Arginine; Gastric Mucosa; Gastrointestinal Tract; Helicobacter Infections; Helic	2013
[Cardiovascular events in chronic advanced renal insufficiency. Current concepts]. Recenti progressi in medicina, 2003, Volume: 94, Issue:3 Topics: Anemia; Arginine; C-Reactive Protein; Cardiovascular Diseases; Humans; Hyperhomocysteinemia; Hyperli	2003
Novel cardiovascular risk factors in end-stage renal disease. Journal of the American Society of Nephrology : JASN, 2004, Volume: 15 Suppl 1 Topics: Arginine; Calcinosis; Cardiovascular Diseases; Humans; Hypertension; Inflammation; Kidney Failure, C	2004
Atherosclerosis in dialyzed patients. Blood purification, 2004, Volume: 22, Issue:1 Topics: Anemia; Animals; Arginine; Arteriosclerosis; Biomarkers; Cause of Death; Comorbidity; Coronary Arter	2004
Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 2005, Volume: 25 Suppl 3 Topics: Arginine; Autonomic Nervous System Diseases; C-Reactive Protein; Cardiovascular Diseases; Humans; Hy	2005
C-reactive protein and asymmetric dimethylarginine: markers or mediators in cardiovascular disorders? Current pharmaceutical design, 2007, Volume: 13, Issue:16 Topics: Animals; Arginine; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Humans;	2007

Article	Year
The Effect of Corrected Inflammation, Oxidative Stress and Endothelial Dysfunction on Fmd Levels in Patients with Selected Chronic Diseases: A Quasi-Experimental Study. Scientific reports, 2020, 06-02, Volume: 10, Issue:1 Topics: Adult; Aged; Antioxidants; Arginine; Atherosclerosis; C-Reactive Protein; Chronic Disease; Dietary S	2020
Resistance training improves sleep quality, redox balance and inflammatory profile in maintenance hemodialysis patients: a randomized controlled trial. Scientific reports, 2020, 07-16, Volume: 10, Issue:1 Topics: Aged; Arginine; Biomarkers; Endothelium; Humans; Inflammation; Male; Middle Aged; Muscle Strength; N	2020
Combination Treatment with Sodium Nitrite and Isoquercetin on Endothelial Dysfunction among Patients with CKD: A Randomized Phase 2 Pilot Trial. Clinical journal of the American Society of Nephrology : CJASN, 2020, 11-06, Volume: 15, Issue:11 Topics: Aged; Amine Oxidase (Copper-Containing); Antioxidants; Arginine; Biomarkers; Cell Adhesion Molecules	2020
Hemodiafiltration is associated with reduced inflammation, oxidative stress and improved endothelial risk profile compared to high-flux hemodialysis in children. PloS one, 2018, Volume: 13, Issue:6 Topics: Adolescent; Arginine; Biomarkers; Child; Female; Hemodiafiltration; Humans; Inflammation; Male; Oxid	2018
Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine. Rejuvenation research, 2019, Volume: 22, Issue:5 Topics: Aged; Arginine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Gly	2019
Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease. PloS one, 2015, Volume: 10, Issue:7 Topics: Adult; Aged; Albuminuria; Arginine; Biomarkers; Blood Glucose; Cell Adhesion Molecules; Comorbidity;	2015
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vascular medicine (London, England), 2007, Volume: 12, Issue:4 Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Brachial Artery; C-Reactive Protei	2007
The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clinical and investigative medicine. Medecine clinique et experimentale, 2008, Volume: 31, Issue:1 Topics: Adult; Arginine; Atherosclerosis; C-Reactive Protein; Endothelium, Vascular; Female; Humans; Inflamm	2008

Article	Year
Impact of zinc oxide nanoparticles on thioredoxin-interacting protein and asymmetric dimethylarginine as biochemical indicators of cardiovascular disorders in gamma-irradiated rats. Environmental toxicology, 2020, Volume: 35, Issue:4 Topics: Animals; Arginine; Biomarkers; Cardiotoxicity; Cell Cycle Proteins; Cytokines; Dose-Response Relatio	2020
Dihydromyricetin increases endothelial nitric oxide production and inhibits atherosclerosis through microRNA-21 in apolipoprotein E-deficient mice. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:10 Topics: Amidohydrolases; Animals; Apolipoproteins E; Arginine; Atherosclerosis; Enzyme Activation; Flavonols	2020
HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation. BMC infectious diseases, 2017, 03-29, Volume: 17, Issue:1 Topics: Arginine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Chromatography, High Pressure L	2017
Relation of Serum ADMA, Apelin-13 and LOX-1 Levels with Inflammatory and Echocardiographic Parameters in Hemodialysis Patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2018, Volume: 22, Issue:2 Topics: Arginine; Biomarkers; C-Reactive Protein; Echocardiography; Enzyme-Linked Immunosorbent Assay; Femal	2018
Distinct Roles of Endothelial Dysfunction and Inflammation in Intracranial Atherosclerotic Stroke. European neurology, 2017, Volume: 77, Issue:3-4 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Arginine; Biomarkers; Endothelium; Female; Hum	2017
Increased Endothelial Dysfunction and Insulin Resistance in Patients with Klinefelter Syndrome. Endocrine, metabolic & immune disorders drug targets, 2018, Volume: 18, Issue:4 Topics: Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studi	2018
Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction. Scientific reports, 2018, 04-30, Volume: 8, Issue:1 Topics: Arginine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium; Feces; Female; Gastrointe	2018
Oxysterols Increase Inflammation, Lipid Marker Levels and Reflect Accelerated Endothelial Dysfunction in Experimental Animals. Mediators of inflammation, 2018, Volume: 2018 Topics: Animals; Arginine; Aryldialkylphosphatase; C-Reactive Protein; Cholesterol; Dyslipidemias; Homocyste	2018
Association of Uremic Toxins and Inflammatory Markers with Physical Performance in Dialysis Patients. Toxins, 2018, 10-01, Volume: 10, Issue:10 Topics: Adult; Aged; Arginine; beta 2-Microglobulin; Biomarkers; C-Reactive Protein; Female; Hand Strength;	2018
The protective effects of polysaccharide extract from Xin-Ji-Er-Kang formula on Ang II-induced HUVECs injury, L-NAME-induced hypertension and cardiovascular remodeling in mice. BMC complementary and alternative medicine, 2019, Jun-13, Volume: 19, Issue:1 Topics: Angiotensin II; Animals; Aorta; Arginine; Blood Pressure; Cytokines; Drug Evaluation, Preclinical; D	2019
Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach. International urology and nephrology, 2013, Volume: 45, Issue:6 Topics: Adult; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Fem	2013
Asymmetric dimethylarginine and asthma: results from the Childhood Asthma Prevention Study. The European respiratory journal, 2013, Volume: 41, Issue:5 Topics: Arginine; Asthma; Australia; Child; Cohort Studies; Cross-Sectional Studies; Female; Humans; Inflamm	2013
Reactive metabolites and AGE-RAGE-mediated inflammation in patients following liver transplantation. Mediators of inflammation, 2013, Volume: 2013 Topics: Antioxidants; Arginine; Female; Glycation End Products, Advanced; Humans; Inflammation; Liver Transp	2013
Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediators of inflammation, 2013, Volume: 2013 Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD34; Arginine; Arthritis, Rhe	2013
ADMA levels and arginine/ADMA ratios reflect severity of disease and extent of inflammation after subarachnoid hemorrhage. Neurocritical care, 2014, Volume: 21, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; C-Reactive Protein; Cytokines; Female; Humans;	2014
Assessment of inflammatory biomarkers and oxidative stress in pulmonary thromboembolism: follow-up results. Inflammation, 2014, Volume: 37, Issue:4 Topics: Adult; Aged; Antioxidants; Arginine; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoxi	2014
Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. Renal failure, 2014, Volume: 36, Issue:5 Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; D	2014
Interactions between inflammatory activation and endothelial dysfunction selectively modulate valve disease progression in patients with bicuspid aortic valve. Heart (British Cardiac Society), 2014, Volume: 100, Issue:10 Topics: Aorta; Aortic Valve; Arginine; Bicuspid Aortic Valve Disease; Biomarkers; Disease Progression; Echoc	2014
Asymmetric dimethylarginine is associated with high-sensitivity C-reactive protein and early carotid atherosclerosis in women with previous gestational diabetes mellitus. Endocrine, 2015, Volume: 48, Issue:2 Topics: Adult; Arginine; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabet	2015
Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology (Oxford, England), 2015, Volume: 54, Issue:7 Topics: Aged; Arginine; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cardiova	2015
Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. Atherosclerosis, 2014, Volume: 237, Issue:1 Topics: Aged; Amidohydrolases; Analysis of Variance; Arginine; Arthritis, Rheumatoid; Female; Genetic Variat	2014
[Effect of matrine on NO and ADMA metabolism pathways in serum and tissues of mice with lipopolysaccharide-induced intestine tissue inflammation]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2014, Volume: 39, Issue:12 Topics: Alkaloids; Animals; Arginine; Humans; Inflammation; Intestinal Diseases; Intestinal Mucosa; Intestin	2014
IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy. BioMed research international, 2014, Volume: 2014 Topics: Adipokines; Antibodies, Monoclonal; Arginine; Female; Humans; Inflammation; Infliximab; Insulin-Like	2014
Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. Journal of hepatology, 2015, Volume: 62, Issue:4 Topics: Albumins; Animals; Arginine; Disease Models, Animal; End Stage Liver Disease; Endothelium, Vascular;	2015
Novel markers of endothelial dysfunction and inflammation in Behçet's disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio. Clinical rheumatology, 2016, Volume: 35, Issue:3 Topics: Adipose Tissue; Adult; Arginine; Behcet Syndrome; Biomarkers; Carotid Intima-Media Thickness; Cross-	2016
Exercise-induced vasodilation in healthy males: A marker of reduced endothelial function. Scandinavian cardiovascular journal : SCJ, 2015, Volume: 49, Issue:3 Topics: Adult; Aged; Arginine; Biomarkers; Endothelium, Vascular; Exercise; Exercise Test; Humans; Hyperemia	2015
The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics. Turkish journal of medical sciences, 2015, Volume: 45, Issue:2 Topics: Adult; Anticholesteremic Agents; Arginine; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; H	2015
Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2015, Volume: 63, Issue:7 Topics: Adult; Arginine; C-Reactive Protein; Case-Control Studies; Female; Humans; Inflammation; Insulin Res	2015
Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:1 Topics: Arginine; Biomarkers; Case-Control Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth F	2016
Relationship between FEV Aging clinical and experimental research, 2017, Volume: 29, Issue:2 Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Fema	2017
The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine. Canadian journal of physiology and pharmacology, 2016, Volume: 94, Issue:7 Topics: Allyl Compounds; Animals; Arginine; Cognitive Dysfunction; Hydrogen Sulfide; Inflammation; Inflammat	2016
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. Journal of pharmaceutical and biomedical analysis, 2016, Sep-10, Volume: 129 Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Fema	2016
Endocan, TGF-beta, and ADMA as Risk Factors for Endothelial Dysfunction and Possible Vascular Disease in Patients with Subclinical Hypothyroidism. Annals of clinical and laboratory science, 2016, Volume: 46, Issue:6 Topics: Adult; Arginine; Biomarkers; Demography; Endothelium, Vascular; Female; Humans; Hypothyroidism; Infl	2016
Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation. Clinical rheumatology, 2017, Volume: 36, Issue:9 Topics: Adult; Arginine; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Case-Control Studies;	2017
Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD. International journal of chronic obstructive pulmonary disease, 2017, Volume: 12 Topics: Aged; Arginine; Asymptomatic Diseases; Atherosclerosis; Biomarkers; Brachial Artery; Case-Control St	2017
Obstructive sleep apnoea syndrome is associated with enhanced sub-clinical inflammation and asymmetric dimethyl-arginine levels in hypertensives. Journal of human hypertension, 2009, Volume: 23, Issue:1 Topics: Adult; Arginine; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studi	2009
Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? The Journal of rheumatology, 2008, Volume: 35, Issue:10 Topics: Adult; Arginine; C-Reactive Protein; Case-Control Studies; Colchicine; Endothelium, Vascular; Famili	2008
Asymmetrical dimethylarginine triggers lipolysis and inflammatory response via induction of endoplasmic reticulum stress in cultured adipocytes. American journal of physiology. Endocrinology and metabolism, 2009, Volume: 296, Issue:4 Topics: 3T3-L1 Cells; Adipocytes; Animals; Arginine; Carrier Proteins; Cells, Cultured; Endoplasmic Reticulu	2009
The conjoint detrimental effect of chronic periodontal disease and systemic inflammation on asymmetric dimethyl-arginine in untreated hypertensive subjects. Atherosclerosis, 2010, Volume: 208, Issue:1 Topics: Arginine; Chronic Disease; Cross-Sectional Studies; Female; Humans; Hypertension; Inflammation; Male	2010
Altered asymmetric dimethyl arginine metabolism in allergically inflamed mouse lungs. American journal of respiratory cell and molecular biology, 2010, Volume: 42, Issue:1 Topics: Amidohydrolases; Animals; Arginine; Asthma; Collagen; Cytosol; Inflammation; Lung; Male; Mice; Mice,	2010
Inflammatory/oxidative stress during the first week after different types of cardiac surgery. Scandinavian cardiovascular journal : SCJ, 2010, Volume: 44, Issue:2 Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiac Surgical Procedures; Cardiopulmonary Bypass;	2010
Increased levels of asymmetric dimethylarginine and C-reactive protein are associated with impaired vascular reactivity in essential hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993), 2010, Volume: 32, Issue:1 Topics: Adult; Aged; Arginine; Blood Flow Velocity; Brachial Artery; C-Reactive Protein; Female; Humans; Hyp	2010
ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 55, Issue:6 Topics: Adult; Albuminuria; Arginine; Blood Pressure; C-Reactive Protein; Creatinine; Cross-Sectional Studie	2010
ADMA is a correlate of insulin resistance in early-stage diabetes independent of hs-CRP and body adiposity. Annales d'endocrinologie, 2010, Volume: 71, Issue:4 Topics: Adiposity; Adult; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Case-Control Studies; Cho	2010
Adipokines, endothelial dysfunction and nutritional status in peritoneal dialysis patients. Scandinavian journal of urology and nephrology, 2010, Volume: 44, Issue:6 Topics: Adiponectin; Adult; Aged; Aldehydes; Arginine; Biomarkers; Body Mass Index; Body Weight; C-Reactive	2010
Plasma dimethylarginines during the acute inflammatory response. European journal of clinical investigation, 2011, Volume: 41, Issue:6 Topics: Acute-Phase Reaction; Aged; Aged, 80 and over; Arginine; Arthroplasty, Replacement, Knee; Cohort Stu	2011
The effects of endothelial dysfunction and inflammation on slow coronary flow. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Arginine; Blood Flow Velocity; C-Reactive Protein; Case-Control Studies; Coronary Angiography; Coron	2010
Inflammation and reduced endothelial function in the course of severe acute heart failure. Translational research : the journal of laboratory and clinical medicine, 2011, Volume: 157, Issue:3 Topics: Acute Disease; Aged; Aged, 80 and over; Arginine; Biomarkers; Case-Control Studies; Endothelium, Vas	2011
Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats. Biomedical research (Tokyo, Japan), 2011, Volume: 32, Issue:2 Topics: Animals; Arginine; Creatinine; Disease Models, Animal; Fibrosis; Hypertension; Hypertrophy, Left Ven	2011
Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:7 Topics: Adult; Aged; Analysis of Variance; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases	2011
HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. Journal of acquired immune deficiency syndromes (1999), 2012, Jun-01, Volume: 60, Issue:2 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Arginine; Biomarkers; CD40 Antigens;	2012
Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome. Inflammation, 2013, Volume: 36, Issue:1 Topics: Arginine; C-Reactive Protein; Continuous Positive Airway Pressure; Humans; Inflammation; Inflammatio	2013
Subarachnoid haemorrhage induces an inflammatory response followed by a delayed persisting increase in asymmetric dimethylarginine. Scandinavian journal of clinical and laboratory investigation, 2012, Volume: 72, Issue:6 Topics: Acute-Phase Reaction; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; Female; Humans	2012
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis. Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2 Topics: Adult; Arginase; Arginine; Biomarkers; Drug Monitoring; Female; Follow-Up Studies; Humans; Inflammat	2012
Disruption of asymmetric dimethylarginine-induced RelA/P65 association with actin in endothelial cells. Acta biochimica et biophysica Sinica, 2013, Volume: 45, Issue:3 Topics: Actins; Active Transport, Cell Nucleus; Arginine; Cell Nucleus; Cytoplasm; Endothelial Cells; Gene E	2013
Effects of asymmetric dimethylarginine on inflammatory cytokines (TNF-α, IL-6 and IL-10) in rats. Toxicology and industrial health, 2015, Volume: 31, Issue:3 Topics: Animals; Arginine; Dose-Response Relationship, Drug; Inflammation; Interleukin-10; Interleukin-6; Ma	2015
Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension. Transplantation, 2002, Nov-27, Volume: 74, Issue:10 Topics: Arginine; Blood Pressure; Female; Heart Transplantation; Humans; Hypertension; Inflammation; Male; M	2002
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:8 Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular System; Cohort Studies; Dialysis; Dis	2005
Gene polymorphism and requirement for vasopressor infusion after cardiac surgery. The Annals of thoracic surgery, 2006, Volume: 82, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Aged; Alleles; Amidohydrolases; Arginine; Cardiac Surgical Pro	2006
Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:3 Topics: Acute Disease; Arginine; Bacterial Infections; Biomarkers; Blood Pressure; C-Reactive Protein; Calci	2007
Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 23, Issue:5-6 Topics: Age of Onset; Arginine; Atherosclerosis; Biomarkers; Carotid Artery, Internal; Carotid Stenosis; Cas	2007
Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free radical research, 2008, Volume: 42, Issue:3 Topics: Animals; Antihypertensive Agents; Arginine; Blood Pressure; Fluorobenzenes; Hydroxymethylglutaryl-Co	2008
Alpha-defensin-like product and asymmetric dimethylarginine increase in mesenteric lymph after hemorrhage in anesthetized rat. Shock (Augusta, Ga.), 2008, Volume: 30, Issue:4 Topics: alpha-Defensins; Anesthesia; Animals; Antimicrobial Cationic Peptides; Arginine; Enzyme-Linked Immun	2008